Short-term Results of Heartmate 3 Ventricular Assist Device Implantation for End-Stage Heart Failure

Basit Öğe Kaydı
dc.contributor.authorOzturk, P.
dc.contributor.authorErtugay, S.
dc.contributor.authorSahutoglu, C.
dc.contributor.authorEngin, C.
dc.contributor.authorNalbantgil, S.
dc.contributor.authorYagdi, T.
dc.contributor.authorOzbaran, M.
dc.date.accessioned2019-10-27T11:09:22Z
dc.date.available2019-10-27T11:09:22Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective. To report our initial experience with Heartmate 3 ventricular assist device (HM3) in cases with end-stage heart failure (ESHF). Methods. Charts of 8 ESHF patients who underwent HM3 implantation in our clinic from January to June 2016 (group 1) and 16 patients who underwent HM2 implantation during 2015 (group 2) were reviewed retrospectively. Demographics as well as pre and early postoperative medical data were noted and statistically analyzed between the 2 groups. Results. No statistical difference was found in age or sex distribution between groups (P >.05). Mean Interagency Registry for Mechanically Assisted Circulatory Support scores were 2.13 +/- 0.99 and 3.38 +/- 0.72 in groups 1 and 2, respectively (P =.020). Mean cardiopulmonary bypass time, and chest tube drainage fluid volume and blood product requirement during intensive care unit (ICU) stay were 64.0 +/- 13.9 minutes, 1,112.5 +/- 516.7 mL, and 318.8 +/- 271.2 mL, respectively, in group 1 and 89.0 +/- 33.3 minutes, 2,081.3 +/- 1,696.0 mL, and 1,118.8 +/- 1,010.8 mL in group 2 (P =.027, P =.019, and P =.040, respectively). Need for surgical revision and early mortality were not evident for group 1, although 4 cases (25.0%) required revision surgery, and early mortality was seen in 3 cases (18.8%) in group 2 (P =.121 and P =.190, respectively). Mean durations of ICU stay and total postoperative hospitalization were 5.9 +/- 2.0 and 18.3 +/- 5.5 days, respectively in group 1 and 6.2 +/- 4.3 and 18.0 +/- 6.9 days in the surviving 13 patients of the group 2 (P =.645 and P =.697, respectively). Conclusions. With its shorter implantation time and reduced blood product requirement in the early postoperative period, the HM3 system was found to be safe and effective in ESHF treatment.en_US
dc.identifier.doi10.1016/j.transproceed.2017.01.034en_US
dc.identifier.endpage602en_US
dc.identifier.issn0041-1345
dc.identifier.issn1873-2623
dc.identifier.issue3en_US
dc.identifier.pmid28340840en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage599en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2017.01.034
dc.identifier.urihttps://hdl.handle.net/11454/32281
dc.identifier.volume49en_US
dc.identifier.wosWOS:000398017900044en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleShort-term Results of Heartmate 3 Ventricular Assist Device Implantation for End-Stage Heart Failureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu